参考文献/References:
[1] Konijnenberg LSF,Damman P,Duncker DJ,et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction[J]. Cardiovasc Res,2020,116(4):787-805.
[2] van Kranenburg M,Magro M,Thiele H,et al. Prognostic value of microvascular obstruction and infarct size,as measured by CMR in STEMI patients[J]. JACC Cardiovasc Imaging,2014,7(9):930-939.
[3] Ndrepepa G,Tiroch K,Keta D,et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction[J]. Circ Cardiovasc Interv,2010,3(1):27-33.
[4] Abbo KM,Dooris M,Glazier S,et al. Features and outcome of no-reflow after percutaneous coronary intervention[J]. Am J Cardiol,1995,75(12):778-782.
[5] Yadav R,Yadav S,Goswami KC,et al. Myocardial preservation during primary percutaneous intervention:it’s time to rethink?[J]. Indian Heart J,2021,73(4):395-403.
[6] Choo EH,Kim PJ,Chang K,et al. The impact of no-reflow phenomena after primary percutaneous coronary intervention:a time-dependent analysis of mortality[J]. Coron Artery Dis,2014,25(5):392-398.
[7] Kleinbongard P,Heusch G. A fresh look at coronary microembolization[J]. Nat R ev Cardiol,2022,19(4):265-280.
[8] Heusch G,Skyschally A,Kleinbongard P. Coronary microembolization and microvascular dysfunction[J]. Int J Cardiol,2018,258:17-23.
[9] Niccoli G,Scalone G,Lerman A,et al. Coronary microvascular obstruction in acute myocardial infarction[J]. Eur H eart J,2016,37(13):1024-1033.
[10] Heusch G,Kleinbongard P,B?se D,et al. Coronary microembolization:from bedside to bench and back to bedside[J]. Circulation,2009,120(18):1822-1836.
[11] Fr?hlich GM,Meier P,White SK,et al. Myocardial reperfusion injury:looking beyond primary PCI[J]. Eur H eart J,2013,34(23):1714-1722.
[12] Bochaton T,Lassus J,Paccalet A,et al. Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients[J]. PLoS One,2021,16(1):e0245684.
[13] Robbers LF,Eerenberg ES,Teunissen PF,et al. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage[J]. Eur H eart J,2013,34(30):2346-2353.
[14] Bulluck H,Rosmini S,Abdel-Gadir A,et al. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling[J]. Circ Cardiovasc Imaging,2016,9(10):e004940.
[15] Sezer M,van Royen N,Umman B,et al. Coronary microvascular injury in reperfused acute myocardial infarction:a view from an integrative perspective[J]. J Am Heart Assoc,2018,7(21):e009949.
[16] Garcia R,Bouleti C,Sirol M,et al. VEGF-A plasma levels are associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction[J]. Int J Cardiol,2019,291:19-24.
[17] Ziegler M,Wang X,Peter K. Platelets in cardiac ischaemia/reperfusion injury:a promising therapeutic target[J]. Cardiovasc Res,2019,115(7):1178-1188.
[18] O’Farrell FM,Attwell D. A role for pericytes in coronary no-reflow[J]. Nat R ev Cardiol,2014,11(7):427-432.
[19] Methner C,Cao Z,Mishra A,et al. Mechanism and potential treatment of the “no reflow”phenomenon after acute myocardial infarction:role of pericytes and GPR39[J]. Am J Physiol Heart Circ P hysiol,2021,321(6):H1030-H1041.
[20] Ge L,Zhou X,Ji WJ,et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow:therapeutic potential of DNase-based reperfusion strategy[J]. Am J Physiol Heart Circ P hysiol,2015,308(5):H500-H509.
[21] Bonaventura A,Vecchié A,Abbate A,et al. Neutrophil extracellular traps and cardiovascular diseases:an update[J]. Cells,2020,9(1):231.
[22] Wang Z,Ren L,Lei L,et al. The relationship between neutrophil counts on admission and angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction[J]. Acta Cardiol,2016,71(2):241-246.
[23] Shavadia JS,Granger CB,Alemayehu W,et al. Novel biomarkers,ST-elevation resolution,and clinical outcomes following primary percutaneous coronary intervention[J]. J Am Heart Assoc,2020,9(13):e016033.
[24] Kurtul A,Acikgoz SK. Usefulness of mean platelet volume-to-lymphocyte ratio for predicting angiographic no-reflow and short-term prognosis after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol,2017,120(4):534-541.
[25] Huang Y,Lei D,Chen Z,et al. Factors associated with microvascular occlusion in patients with ST elevation myocardial infarction after primary percutaneous coronary intervention[J]. J Int Med R es,2021,49(6):3000605211024490.
[26] Niccoli G,Montone RA,Ibanez B,et al. Optimized treatment of ST-elevation myocardial infarction[J]. Circ R es,2019,125(2):245-258.
[27] Bulluck H,Foin N,Tan JW,et al. Invasive assessment of the coronary microcirculation in reperfused ST-segment-elevation myocardial i nfarction patients:where do we stand?[J]. Circ Cardiovasc I nterv,2017,10(3):e004373.
[28] Sun Z,Zeng J,Huang H. Intracoronary injection of tirofiban prevents microcirculation dysfunction during delayed percutaneous coronary intervention in patients with acute myocardial infarction[J]. Int J Cardiol,2016,208:137-140.
[29] Zeng Q,Zhang LD,Wang W. A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention[J]. Anatol J Cardiol,2021,25(1):7-16.
[30] Meier D,Fournier S,Masci PG,et al. Impact of manual thrombectomy on microvascular obstruction in STEMI patients[J]. Catheter C ardiovasc I nterv,2021,97(6):1141-1148.
[31] L?nborg J,Engstr?m T,Ahtarovski KA,et al. Myocardial damage in patients with deferred stenting after STEMI:a DANAMI-3-DEFER substudy[J]. J Am Coll Cardiol,2017,69(23):2794-2804.
[32] Mahmoud AN,Saad M,Elgendy AY,et. Deferred or immediate stent implantation for primary percutaneous coronary intervention:a meta-analysis of randomized trials[J]. Catheter Cardiovasc I nterv,2018,91(2):260-264.
[33] Pradhan A,Bhandari M,Vishwakarma P,et al. Deferred stenting for heavy thrombus burden during percutaneous coronary intervention for ST-elevation MI[J]. Eur Cardiol,2021,16:e08.
[34] Scarsini R,Terentes-Printzios D,Shanmuganathan M,et al. Pressure-controlled intermittent coronary sinus occlusion improves the vasodilatory microvascular capacity and reduces myocardial injury in patients with STEMI[J]. Catheter Cardiovasc Interv,2022,99(2):329-339.
[35] Niccoli G,Spaziani C,Crea F. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial[J]. J Am Coll Cardiol,2014,63(14):1454-1455.
[36] Broch K,Anstensrud AK,Woxholt S,et al. Randomized trial of interleukin-6 receptor inhibition in patients withacute ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol,2021,77(15):1845-1855.
相似文献/References:
[1]鲁鹏,综述,蔡琳,等.冠状动脉钙化的研究新进展[J].心血管病学进展,2016,(2):176.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.021]
LU Peng,CAI Lin,HUANG Wei.New Progress of Coronary Artery Calcification[J].Advances in Cardiovascular Diseases,2016,(3):176.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.021]
[2]郑剑峰 邱洪.冠状动脉钙化研究进展[J].心血管病学进展,2020,(4):338.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.002]
ZHENG JianFengQIU Hong.Coronary Artery Calcification[J].Advances in Cardiovascular Diseases,2020,(3):338.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.002]
[3]孙一博 孙莉萍 董建增.血管炎的冠状动脉风险及手术治疗进展[J].心血管病学进展,2020,(8):821.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.010]
SUN YiboSUN LipingDONG Jianzeng.Coronary Risk and Progress in Surgical Therapy of Vasculitis[J].Advances in Cardiovascular Diseases,2020,(3):821.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.010]
[4]田婷 罗俊一 杨毅宁.一种罕见的冠状动脉异常——编织样冠状动脉[J].心血管病学进展,2020,(9):943.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.014]
TIAN Ting,LUO Junyi,YANG Yining.An Extremely Rare Anomaly of Coronary Artery[J].Advances in Cardiovascular Diseases,2020,(3):943.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.014]
[5]白梦雪 赵慧强.低分子右旋糖酐光学相干断层成像技术在冠状动脉疾病中的应用进展[J].心血管病学进展,2022,(2):103.[doi:10.16806/j.cnki.issn.1004-3934.20.02.003]
BAI MengxueZHAO Huiqiang.Application of Low Molecular Dextran Optical Coherence Tomography?n Coronary Arteries Disease[J].Advances in Cardiovascular Diseases,2022,(3):103.[doi:10.16806/j.cnki.issn.1004-3934.20.02.003]
[6]陈璐 王国宏 郭彩霞.冠状动脉CT血管成像对冠心病预后预测价值及治疗策略指导意义[J].心血管病学进展,2022,(2):108.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.004]
CHEN Lu,WANG Guohong,GUO Caixia.The Value of Coronary CT Angiography In Predicting the Prognosis and Treatment Strategies of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(3):108.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.004]
[7]李俊鹏 刘建 刘娜 杨欣荣 高婷 赵正凯.“三低”技术在CT体部血管一站式成像的应用价值[J].心血管病学进展,2022,(7):662.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
LI Junpeng,LIU Jian,LIU Na,et al.Application of Three Lows Technology in One-Stop Imaging of CT Body Vessels[J].Advances in Cardiovascular Diseases,2022,(3):662.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[8]李依珂 高艳香 李青 郭紫玉 郑金刚.冠状动脉微循环侵入性检测方法研究进展[J].心血管病学进展,2023,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.008]
LI Yike,GAO Yanxiang,LI Qing,et al.Invasive Assessment of Coronary Microcirculation[J].Advances in Cardiovascular Diseases,2023,(3):30.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.008]
[9]徐明成 赵玉娟.甘油三酯葡萄糖指数对动脉粥样硬化性心血管疾病的预测价值[J].心血管病学进展,2023,(9):810.[doi:10.16806/j.cnki.issn.1004-3934.202.09.010]
Xu Mingcheng,ZHAO Yujuan.Predictive Value of Triglyceride Glucose Index in Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(3):810.[doi:10.16806/j.cnki.issn.1004-3934.202.09.010]